转移性移行细胞癌二线全身治疗的监管机构批准建议。 - Suppr

Suppr

超能文献

Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.

作者信息

Sonpavde Guru, Rosenberg Jonathan E, Hahn Noah M, Galsky Matthew D, Bangs Rick, Sternberg Cora N, Vogelzang Nicholas J

出版信息

J Clin Oncol. 2010 May 1;28(13):e205-7; author reply e208. doi: 10.1200/JCO.2009.27.1114. Epub 2010 Feb 16.

DOI:10.1200/JCO.2009.27.1114

PMID:20159797

Abstract

摘要

相似文献

Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.转移性移行细胞癌二线全身治疗的监管机构批准建议。

J Clin Oncol. 2010 May 1;28(13):e205-7; author reply e208. doi: 10.1200/JCO.2009.27.1114. Epub 2010 Feb 16.

Novel agents for muscle-invasive and advanced urothelial cancer.用于肌肉浸润性和晚期尿路上皮癌的新型药物

BJU Int. 2008 Apr;101(8):937-43. doi: 10.1111/j.1464-410X.2007.07326.x. Epub 2007 Nov 13.

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

J Urol. 1992 Nov;148(5):1625-6.

Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review.维莫非尼作为铂类耐药转移性尿路上皮癌二线治疗药物：一项综述。

Anticancer Drugs. 2011 Jan;22(1):9-17. doi: 10.1097/CAD.0b013e3283404db0.

Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract.重组人粒细胞集落刺激因子对接受甲氨蝶呤/长春碱/阿霉素/顺铂治疗的尿路移行细胞癌患者的影响。

Semin Oncol. 1994 Feb;21(1 Suppl 1):70-4.

Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.在接受基于顺铂化疗的局部晚期和/或转移性移行细胞癌的连续单机构患者中，反应的预测因素和长期生存的预后因素。

Acta Oncol. 2009;48(3):411-7. doi: 10.1080/02841860802325932.

[Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].[甲氨蝶呤、长春花碱、阿霉素和顺铂联合化疗（M-VAC）治疗晚期尿路上皮癌的经验]

Hinyokika Kiyo. 1988 Aug;34(8):1371-5.

Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.M-VAC化疗联合轻度热疗治疗晚期或转移性尿路上皮移行细胞癌的新治疗策略的初步结果

Cancer Chemother Pharmacol. 2009 Nov;64(6):1079-83. doi: 10.1007/s00280-009-0964-2. Epub 2009 Mar 11.

Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.多西他赛：新适应症。非小细胞肺癌的一线治疗：无进展。

Prescrire Int. 2005 Feb;14(75):16-8.

Systemic therapy for metastatic urothelial carcinoma.转移性尿路上皮癌的全身治疗

BJU Int. 2008 Apr;101(7):795-803. doi: 10.1111/j.1464-410X.2007.07356.x. Epub 2007 Dec 5.

引用本文的文献

Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as second-line therapy for patients with advanced urothelial cancer.奥沙利铂、5-氟尿嘧啶和亚叶酸钙（FOLFOX）作为晚期尿路上皮癌患者的二线治疗方案。

Oncotarget. 2016 Sep 6;7(36):58579-58585. doi: 10.18632/oncotarget.10463.

Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?转移性尿路上皮癌患者从多西他赛二线化疗中获益吗？

Clin Transl Oncol. 2014 Jan;16(1):102-6. doi: 10.1007/s12094-013-1045-x. Epub 2013 Apr 20.

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.既往化疗时间可增强二线晚期尿路上皮癌的预后风险分组：汇总前瞻性 2 期试验的回顾性分析。

Eur Urol. 2013 Apr;63(4):717-23. doi: 10.1016/j.eururo.2012.11.042. Epub 2012 Nov 26.

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.转移性肾细胞癌的靶向治疗全面综述。

Curr Cancer Drug Targets. 2012 Sep;12(7):857-72. doi: 10.2174/156800912802429265.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验